Ibrance (palbociclib) vs Xeloda ()
Ibrance (palbociclib) vs Xeloda ()
Ibrance (palbociclib) is a targeted therapy known as a CDK4/6 inhibitor used primarily in combination with hormonal therapy for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Xeloda (capecitabine) is an oral chemotherapy drug that is metabolized into 5-fluorouracil (5-FU) in the body, and it's used to treat various types of cancer, including breast cancer, colorectal cancer, and gastric cancer. When deciding between Ibrance and Xeloda, a patient's specific type of cancer, stage, previous treatments, and overall health must be considered, and the choice should be made in consultation with an oncologist to determine the most appropriate and effective treatment plan.
Difference between Ibrance and Xeloda
| Metric | Ibrance (palbociclib) | Xeloda (capecitabine) |
|---|---|---|
| Generic name | Palbociclib | Capecitabine |
| Indications | HR-positive, HER2-negative advanced or metastatic breast cancer | Metastatic colorectal cancer, metastatic breast cancer |
| Mechanism of action | Inhibits cyclin-dependent kinases CDK4 and CDK6 | Prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body |
| Brand names | Ibrance | Xeloda |
| Administrative route | Oral | Oral |
| Side effects | Neutropenia, leukopenia, infections, fatigue | Hand-foot syndrome, diarrhea, nausea, fatigue |
| Contraindications | Hypersensitivity to palbociclib or any component of the formulation | Hypersensitivity to capecitabine or fluorouracil (5-FU) |
| Drug class | CDK4/6 inhibitor | Antimetabolite, fluoropyrimidine |
| Manufacturer | Pfizer | Roche |
Efficacy
Ibrance (Palbociclib) Efficacy in Breast Cancer
Ibrance (palbociclib) is a targeted therapy drug approved for the treatment of certain types of breast cancer. Specifically, it is used for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib works by inhibiting cyclin-dependent kinases (CDK) 4 and 6, which are proteins that regulate cell division. By blocking these proteins, Ibrance can slow down the growth and spread of cancer cells.
Clinical trials have demonstrated that when used in combination with hormone therapy, such as an aromatase inhibitor or fulvestrant, Ibrance can significantly extend progression-free survival compared to hormone therapy alone. This has been observed in both premenopausal and postmenopausal women with advanced breast cancer. Patients receiving Ibrance in combination with letrozole or fulvestrant experienced a delay in disease progression, indicating the drug's efficacy in improving clinical outcomes in this patient population.
Xeloda (Capecitabine) Efficacy in Breast Cancer
Xeloda (capecitabine) is an oral chemotherapy drug that is metabolized in the body to 5-fluorouracil (5-FU), a substance that interferes with the DNA synthesis of cancer cells, ultimately leading to their death. Xeloda is approved for the treatment of metastatic breast cancer, particularly in patients who have not responded to other chemotherapy treatments, including anthracyclines and taxanes, or when further anthracycline therapy is not indicated.
The efficacy of Xeloda in breast cancer has been established through several clinical trials. In patients with metastatic breast cancer, Xeloda has been shown to achieve response rates comparable to standard intravenous chemotherapy regimens, with some studies suggesting a favorable safety profile. Additionally, Xeloda has been used effectively in combination with other drugs, such as docetaxel, to improve outcomes in metastatic breast cancer patients. The drug's oral administration offers a convenient treatment option that can be taken at home, which may improve quality of life for patients undergoing cancer treatment.
Regulatory Agency Approvals
Ibrance
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Xeloda
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Ibrance or Xeloda today
If Ibrance or Xeloda are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us